Diagnostic significance of Drs. Wyatt & Chi's recent European Urology publication (video link)

Date Posted: 
2017-03-09

A study led by Drs. Kim Chi & Alex Wyatt demonstrated that metastatic castration-resistant prostate cancer patients with germline DNA repair defects respond poorly to androgen receptor-targeted therapy. However, biallelic gene loss was robustly detected in circulating tumor DNA, suggesting that this patient subset could be prioritized for therapies exploiting defective DNA repair using a liquid biopsy.  Click here for the publication, "Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer" in the journal European Urology (March 2 issue, link opens in new window).

Click here to see a Prostate Cancer Canada video (YouTube) of Dr. Wyatt discussing the diagnostic significance of the article.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

PCF BC

Ride to Live 2018 and 50-50 Draw: May 27

The West Coast Motorcycle Ride to Live, raising funds for Prostate Cancer Foundation BC, takes place on Sunday May 27, 2018 in Vancouver, Victoria & the Fraser Valley. Follow the links to join a ride or donate to a rider; or to buy a ticket for a 50/50 draw (BC residents only).

Employment

Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.